Blood Biomarkers for Screening of Alzheimer's Disease

Blood-based Biomarkers for Early Alzheimer's Disease Screening

The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are:

• to identify core blood biomarker suitable for early screening of AD.
• to establish a comprehensive model for the early identification of AD.

Inclusion Criteria:

• Age ≥ 50 years;
• AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;
• Signed informed consent form.

Exclusion Criteria:

• The presence of other disorders that can cause cognitive impairment;
• Unable to cooperate with the completion of cognitive assessment;
• Refusal to draw blood.